Bristol Myers Squibb is deepening its bet on artificial intelligence, expanding its partnership with chipmaker NVIDIA to accelerate the hunt for new medicines.
The drugmaker is buying NVIDIA's latest AI computing system for its drug research, according to Crypto Briefing. Pharmaceutical Executive and Quartz both frame the move as an expansion of an existing collaboration built around an NVIDIA AI supercomputer dedicated to drug discovery.
At the center of the deal is NVIDIA's newest hardware. According to a report on Yahoo Finance, Bristol Myers Squibb will deploy NVIDIA's Vera Rubin systems, giving the company what it calls the most powerful AI computing infrastructure in life sciences.
The New Jersey Business & Industry Association describes the goal plainly: the expanded partnership is meant to speed up drug discovery. In practical terms, that means using massive computing power to sift through molecular data and identify promising drug candidates faster than traditional lab work alone typically allows.
For NVIDIA, the agreement is another sign that its chips are moving well beyond tech companies and into industries like pharmaceuticals, where drug development has long been slow, expensive, and uncertain. For Bristol Myers Squibb, it signals a wager that heavier computing muscle can shorten the path from research to real treatments.
Why it matters: if AI-driven computing can meaningfully accelerate how new drugs are found, deals like this one could reshape how quickly — and how cheaply — future medicines reach patients.